Unlock instant, AI-driven research and patent intelligence for your innovation.

Remedies

A technology of drugs and substances, applied in the field of medicine, to solve problems such as danger

Inactive Publication Date: 2002-05-01
TAKARA HOLDINGS
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, surgical administration of NGF directly to

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Remedies
  • Remedies
  • Remedies

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0035] There is no limitation on the production method of 4-hydroxy-2-cyclopenten-1-one (hereinafter referred to as 4HCP) used in the present invention. 4HCP can be produced by chemical synthesis. Its known synthetic methods include as follows: Tanaka, T. et al [Tetrahedron, 32:1713 (1976)], Nara, M. et al [Tetrahedron, 36:3161 (1980)] and Gill, M. et al [Aust.J . Chem., 34:2587 (1981)]. These preparation methods involve many synthetic steps, are complicated, have low yields, and are inefficient. 4HCP can be obtained in high yield by a one-step reduction of 4-cyclopentene-1,3-dione with cerium(III) chloride and sodium borohydride.

[0036] Cyclopentenone produced in heat-treated products of at least one substance selected from the group consisting of pentoses, pentose derivatives, pentose-containing compounds, and pentose-containing derivatives, and purified products thereof can be used. compounds of matter. These heat-treated products containing 4HCP and partially purifie...

Embodiment 1

[0139] Rat fibroblast L-M cells (ATCC CCL-1.2) were mixed with 1.0×10 5 Cells / ml were suspended in M199 medium (Gibco) containing 0.5% Bacto Peptone (Gibco). 1 ml of this suspension was inoculated into each well of a 24-well plate. Cells were grown aseptically. After culturing for 2 days, the medium was removed and replaced with M199 medium containing 0.5% bovine serum albumin (Sigma). Then, cyclopentenone (final concentration 1-25 μM), 4HCP (Aldrich) (final concentration 12.5c) or dipropionylcyclopentenone (final concentration 3.1-9.4 μM) was added thereto. The plates were then incubated for 24 hours.

[0140] After incubation, the concentration of nerve growth factor in the medium was measured by enzyme immunoassay (NGF Emax Immuno Assay System: Promega). As a result, cyclopentenone, 4HCP and dipropionylcyclopentenone enhanced the production of nerve growth factor by L-M cells in a concentration-dependent manner. The results are shown in Tables 1-4.

[0141] Table 1: C...

Embodiment 2

[0149] MRC-5 cells (CCL-171, Dainippon Pharmaceutical) were treated with 1×10 5 Cells / ml were suspended in DME medium (BioWhittaker) containing 10% fetal bovine serum. 500 µl of this suspension was added to each well of a 48-well culture plate. at 37°C and 5% CO 2 After culturing in the presence for 24 hours, the medium was replaced with DME medium containing 1% fetal bovine serum. Then, add a sample to it. The plates were incubated for an additional 24 hours. The medium was then collected, and the amount of HGF in the medium was measured using Quantikine Human Hepatocyte Growth Factor (HGF) ELISA Kit (Funakoshi). Take the negative control as 100% to express the production of HGF. In this case, the production of negative control HGF was 7.2 ng / ml. Cyclopentenone (20, 40 or 160 μM final concentration), GM (20, 40, 80 or 160 μM final concentration) or dipropionylcyclopentenone (32 or 64 μM final concentration) were added as samples. As a negative control, add the same vol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Remedies or preventives for diseases with a need for the reinforcement of the production of growth factor and/or diseases with a need for the reinforcement of the production of interleukin-12, characterized by containing as the active ingredient a compound selected from among 4,5-dihydroxy-2-cyclopenten-1-one represented by formula (I), 4-hydroxy-2-cyclopenten-1-one and derivatives thereof.

Description

technical field [0001] The present invention relates to pharmaceutical compositions, preparations, or foods or beverages which are effective for the treatment or prevention of diseases requiring enhanced production of cell growth factors. Background technique [0002] Growth factors are a class of substances that promote cell growth / proliferation in minute amounts. They control the proliferation, elongation, enlargement, differentiation, etc. of cells. Known physiological functions of growth factors include growth-promoting activity, insulin-like activity, anabolic, osteogenic activity, cell-growth-promoting activity, neurotrophic factor-like activity, erythropoietin-like activity, intrauterine growth-promoting activity, and increased renal blood flow / Protect kidney cell activity and enhance immune activity. Therefore, they are expected to ameliorate unresponsiveness to growth hormone, diabetes and catabolic conditions, and are useful in, for example, osteoporosis, disea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A23L1/0522A23L1/09A23L2/52A23L5/20A23L29/256A23L33/00A61K8/70A61K8/73A61K31/122A61K31/70A61K31/7016A61K31/702A61K31/715A61K31/737A61P1/16A61P3/10A61P25/28A61P35/00A61P43/00A61Q19/00
CPCA23L1/0156A23L1/29A61K31/702A23L1/0532A23L1/09A61K31/7016A61K31/715A61K31/737A23L1/05223A23L2/52A23L1/097A61K31/122A61K31/70A23L5/273A23L29/219A23L29/256A23L29/30A23L29/37A23L33/00A23L5/00A61P1/16A61P25/28A61P3/10A61P35/00A61P43/00
Inventor 大野木宏明山香织富永隆生西山英治务华康巽容子佐川裕章加藤郁之进
Owner TAKARA HOLDINGS